- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Wealth Planning, Administration, and Disputes
-
May 26, 2020K. Craig Wildfang Named Titan of the Plaintiffs Bar by Law360
-
May 14, 2020Aaron Sheanin Appointed to Board of Directors for Legal Aid at Work
-
May 13, 2020Meegan Hollywood Named to Global Competition Review’s 40 Under 40
-
June 23, 2020Pride Month CLE: Current Legal Issues Impacting LGBTQ Equity
-
September 17, 202018th Annual Golf Tournament for the Benefit of Special Olympics Massachusetts
-
May 26, 2020Joint ventures and the COVID-19 pandemic
-
May 18, 2020DOJ Signs Off On First COVID-Related Competitor Collaboration Not Involving Medical Supplies
-
May 11, 2020Competitor Collaborations and Covid-19—Antitrust Considerations
Avandia's Serious Safety Problems
Summer 2010
Copyright 2010. All rights reserved.
In the third quarter of 2009, Avandia had the dubious distinction of ranking first among all prescribed drugs in the number of serious, disability and fatal problems reported to the FDA, including over 300 deaths reported to the FDA in the third quarter alone.[1] Manufactured by GlaxoSmithKline (GSK), Avandia is a drug for Type 2 diabetics designed to help keep blood sugar levels stable. But, it has been associated with multiple safety issues, including heart attacks, congestive heart failure and bone fractures.[2] In 2009, GSK reported the results of a five-year study which showed a twice as many patients on Avandia experienced heart failure causing hospital admission or death than those in the control group.[3] In February 2010, the FDA announced it conducting a safety review of the drug, with results expected in July 2010.[4]
Robins, Kaplan, Miller & Ciresi L.L.P. is investigating potential claims on behalf of Avandia patients. If you wish to speak to us about a potential claim or an injury caused by Avandia, please call Kathy Neuman, R.N., B.S.N. at 1-800-553-9910 or contact her via email at contact us.
[2] PD Home et al. Rosiglitazone Evaluated for Cardiovascular Outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized open-label trial. Lancet. 2009; 373 (9681):2125-2135; YK Loke et al. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta analysis. CMAJ. 2009; 180(1):32-9.
[3] PD Home, supra note 7.
[4] http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201418.htm#sa
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.
Related Professionals
Kate E. Jaycox
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.